EA200702361A1 - АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ - Google Patents

АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Info

Publication number
EA200702361A1
EA200702361A1 EA200702361A EA200702361A EA200702361A1 EA 200702361 A1 EA200702361 A1 EA 200702361A1 EA 200702361 A EA200702361 A EA 200702361A EA 200702361 A EA200702361 A EA 200702361A EA 200702361 A1 EA200702361 A1 EA 200702361A1
Authority
EA
Eurasian Patent Office
Prior art keywords
cspcna
isoforms
application
antibodies against
isoform
Prior art date
Application number
EA200702361A
Other languages
English (en)
Inventor
Роберт Дж. Хикки
Линда Х. Малкас
Лорен Шнапер
Original Assignee
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
СиЭс-КИЗ, ИНК.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн, СиЭс-КИЗ, ИНК. filed Critical Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн
Publication of EA200702361A1 publication Critical patent/EA200702361A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3015—Breast
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57496—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving intracellular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups

Abstract

Антитела специфически связываются лишь с раковой специфической изоформой ядерного антигена пролиферирующих клеток (csPCNA), но не связываются с незлокачественной изоформой ядерного антигена пролиферирующих клеток (nmPCNA). Раскрываются способы и композиции для выявления присутствия csPCNA изоформы.
EA200702361A 2005-04-27 2006-04-27 АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ EA200702361A1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US67527505P 2005-04-27 2005-04-27
US68961405P 2005-06-09 2005-06-09
PCT/US2006/016096 WO2006116631A2 (en) 2005-04-27 2006-04-27 Cancer specific pcna isoform binding antibodies and uses thereof

Publications (1)

Publication Number Publication Date
EA200702361A1 true EA200702361A1 (ru) 2008-04-28

Family

ID=37215524

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200702361A EA200702361A1 (ru) 2005-04-27 2006-04-27 АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ

Country Status (10)

Country Link
US (4) US20080206140A1 (ru)
EP (1) EP1874823B1 (ru)
JP (1) JP2008539271A (ru)
AU (1) AU2006239318A1 (ru)
BR (1) BRPI0607676A2 (ru)
CA (1) CA2605745A1 (ru)
EA (1) EA200702361A1 (ru)
HK (1) HK1110338A1 (ru)
MX (1) MX2007013584A (ru)
WO (1) WO2006116631A2 (ru)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
CA2638866C (en) 2006-02-17 2015-11-10 Indiana University Research And Technology Corporation Peptide based inhibition of capcna protein-protein interactions in cancer
EP2913057B1 (en) 2008-07-24 2017-09-06 Indiana University Research and Technology Corporation Cancer peptide therapeutics
WO2011044374A1 (en) * 2009-10-07 2011-04-14 Indiana University Research And Technology Corporation Capcna peptide therapeutics for cancer
US8455200B2 (en) 2009-10-15 2013-06-04 Traxxsson, Llc Measurement of PKA for cancer detection
WO2012173677A2 (en) * 2011-03-23 2012-12-20 Indiana University Research And Technology Corporation Anticancer therapeutic agents
EP3916007A1 (en) * 2014-03-24 2021-12-01 Immco Diagnostics, Inc. Improved anti-nuclear antibody detection and diagnostics for systemic and non-systemic autoimmune disorders
US10420840B2 (en) 2015-04-10 2019-09-24 Rll, Llc Anticancer therapeutic agents
JP2020514256A (ja) 2016-12-15 2020-05-21 ザ ナショナル インスティチュート フォー バイオテクノロジー イン ザ ネゲヴ，リミテッド 抗ｐｃｎａモノクローナル抗体及びその使用
WO2019241730A2 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MA55805A (fr) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V Inc Métodes de modulation de l'activité immunitaire
EP4076434A1 (en) 2019-12-17 2022-10-26 Flagship Pioneering Innovations V, Inc. Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
CN116096906A (zh) 2020-06-29 2023-05-09 旗舰创业创新五公司 工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
US20220325287A1 (en) 2021-03-31 2022-10-13 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
WO2023278641A1 (en) 2021-06-29 2023-01-05 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001518453A (ja) * 1997-09-29 2001-10-16 ユニバーシティ オブ メリーランド， ボルチモア 悪性腫瘍の生体マーカーとしての改変されたｄｎａシンセソーム成分
US7294471B2 (en) * 2002-02-27 2007-11-13 Cskeys, Llc Method for purifying cancer-specific proliferating cell nuclear antigen
EP1998177A3 (en) * 2003-01-06 2009-02-18 Wyeth Compositions and methods for diagnosing and treating colon cancers
US8574848B2 (en) * 2006-09-13 2013-11-05 Oncimmune Ltd. Immunoassay methods

Also Published As

Publication number Publication date
EP1874823A2 (en) 2008-01-09
BRPI0607676A2 (pt) 2009-09-22
AU2006239318A1 (en) 2006-11-02
EP1874823B1 (en) 2016-01-13
MX2007013584A (es) 2008-04-22
WO2006116631A2 (en) 2006-11-02
US9006396B2 (en) 2015-04-14
AU2006239318A8 (en) 2006-11-02
WO2006116631A3 (en) 2007-03-22
US20120244076A1 (en) 2012-09-27
CA2605745A1 (en) 2006-11-02
HK1110338A1 (zh) 2008-07-11
US20080206140A1 (en) 2008-08-28
US20180362626A1 (en) 2018-12-20
US20150259407A1 (en) 2015-09-17
JP2008539271A (ja) 2008-11-13

Similar Documents

Publication Publication Date Title
EA200702361A1 (ru) АНТИТЕЛА ПРОТИВ csPCNA ИЗОФОРМЫ И ИХ ПРИМЕНЕНИЕ
EA200970210A1 (ru) Prlr-специфическое антитело и его применения
CY1122210T1 (el) Ανθρωπινα αντισωματα anti-sod1
CY1123518T1 (el) Ανθρωπινα αντισωματα enanti-tau
BR112012023010A2 (pt) "anticorpo ou fragmento de ligação a antígeno do mesmo que se liga especificamente a cd37, imunoconjugado compreendendo os mesmos, uso dos referidos anticorpo, fragmento e imunoconjugado, composição compreendendo os mesmos, kit, célula isolada, bem como método in vitro para inibir o crescimento de uma célula que expressa cd37"
PH12016500658B1 (en) Human anti-alpha-synuclein autoantibodies
EA201270654A1 (ru) Моноклональные антитела, связывающие b7h6, и их применение
TR201910348T4 (tr) Matriks metalloproteinaz 9 için antikorlar.
IN2009KN02404A (ru)
NZ601615A (en) Antibodies that bind to lysyl oxidase-like 2 (loxl2) and methods of use therefor
CY1117942T1 (el) Αντισωματα προσδεματος επαγωγης πολλαπλασιασμου (april)
CL2008002085A1 (es) Anticuerpo humanizado anti-cd79b/igbeta/b29; polinucleotido codificacnte, vector, celula huesped; metodo de fabricacion; inmunoconjugado; composicion farmaceutica; uso para tratar cancer; metodo in vitro para determinar presencia de cd79b, oinhibir crecimiento de celulas quqe expresa cd79b; ensayo in vitro para detectar celulas b
MX2018008680A (es) Moleculas de union especifica a proteina de union a adn de respuesta transactiva de 43 kda (tdp-43).
MX2009003306A (es) Anticuerpos humanos que se unen a cxcr4 y sus usos.
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
BR112013010213A2 (pt) anticorpos que unem ligantes solúveis de receptores de célula t
BRPI0607323B8 (pt) composições, usos de polipeptídeos e de anticorpos, bem como kits para a detecção de anticorpo que se liga especificamente a um polipeptídeo
TR201808535T4 (tr) İki veya daha fazla sayıda antijen molekülüne tekrar tekrar bağlanabilen antijen bağlanma molekülü.
BRPI0906435B8 (pt) Anticorpo anti-cd79b quimérico, composto conjugado, formulação farmacêutica, método para determinar a presença da proteína cd79b, ensaio para detectar células de câncer, método para inibir proliferação celular, usos de um anticorpo, de um composto conjugado e de uma formulação farmacêutica, e método para a fabricação de um composto conjugado
EA200801847A1 (ru) ПЕПТИДНОЕ ИНГИБИРОВАНИЕ ВЗАИМОДЕЙСТВИЯ caPCNA ПРИ РАКЕ
BRPI0812488A2 (pt) Anticorpos anti-cd44 humanizados e quiméricos que mediam citotoxidade de célula de câncer, usos dos mesmos, ensaios de ligação, métodos, composições e kit de ensaio
EA201590459A1 (ru) Специфические антитела к островковому амилоидному полипептиду человека (hiapp) и их применение
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
MA33276B1 (fr) Anticorps spécifiques à la cadhérine-17
MX2009005103A (es) Conjugado anti-idiotipo y su uso como un estandar en un inmunoensayo.